anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Asthma is a heterogeneous disease that affects millions of children and adults. There is a lack of objective gold standard diagnosis that spans the ages; instead, diagnoses are made by clinician assessment based on a cluster of signs, symptoms and objective tests dependent on age. Yet, there is a clear morbidity associated with chronic asthma symptoms. Machine learning has become a popular tool to improve asthma diagnosis and classification. There is a paucity of literature on the use of Bayesian machine learning algorithms to predict asthma diagnosis in children. This paper develops a prediction model using the Bayesian additive regression trees (BART) and compares its performance to various machine learning algorithms in predicting the diagnosis of childhood asthma.
METHODS: Clinically relevant variables collected at or before 3 years of age from 2794 participants in the CHILD Cohort Study were used to predict physician-diagnosed asthma at age 5. BART and six other commonly used machine learning algorithms, namely adaptive boosting, logistic regression, decision tree, neural network, random forest, and support vector machine were trained. Measures of performance including sensitivity, specificity, and area under the receiver operating characteristic (ROC) curve were calculated. The confidence intervals were calculated using Bootstrapping samples. Important predictors and interaction effects associated with asthma were also identified using BART.
RESULTS: BART, logistic regression and random forest showed the highest area under the ROC curve compared to other machine learning algorithms. Based on BART, recurrent wheeze, respiratory infection and food sensitization at 3 years of age were the most important predictors. The three most important interaction effects were found to be interaction terms of respiratory infection at 3 years and recurrent wheezing at 3 years, maternal asthma and paternal asthma, and maternal wheezing and inhalant sensitization of child at 3 years.
CONCLUSIONS: BART demonstrated promising prediction performance when compared to other machine learning algorithms. Future research could validate the BART in an external cohort to evaluate its reliability and generalizability.
INTRODUCTION: Patients with Human Papillomavirus (HPV+)-associated Laryngeal Squamous Cell Carcinoma (LSCC) exhibit dramatically improved survival relative to those with HPV-Negative (HPV-) tumors. In this study, the authors aimed to investigate the radiosensitivity of all available confirmed HPV+ and HPV-LSCC cells in vitro and in vivo.
METHODS: Primary LSCC cells were generated from tumor specimens obtained from patients. Real-time PCR was performed to confirm HPV infection and the expression of HPV-related genes (E6 and E7), p53, and pRB. Clonogenic survival assays, western blotting, and flow cytometry were used to assess radiation sensitivity, apoptosis, and the expression of p53 and pRB. p53 and pRB knockout cells were generated using CRISPR/Cas9 technology.
RESULTS: HPV+ LSCC cells displayed enhanced radiation sensitivity compared to HPV- cells. Radiation-induced apoptosis in HPV+ LSCC cells, accompanied by increased levels of p53 and pRB. Knockout of p53 or pRB led to radiation resistance and attenuated radiation-induced apoptosis in HPV+ LSCC cells. In vivo experiments showed similar results, where knockout of p53 or pRB decreased radiosensitivity in tumor-bearing mice.
CONCLUSION: The present findings demonstrated that HPV+ LSCC cells displayed obvious inherent radiation sensitivity, corresponding to increased apoptosis following radiation exposure. Mechanism study showed that the expression of p53 and pRB in HPV+ cells are required for radiation sensitivity. These findings highlight a novel mechanism by which p53 and pRB play key roles in the radiation sensitivity of HPV+ LSCC compared to HPV-LSCC.
Methods, computer systems and computer readable media for communicating data to and receiving data from ventilators in a healthcare setting and displaying the data on a user device are provided. A ventilator order is communicated to a ventilator associated with a patient. A continuous data feed is received from the ventilator. In embodiments, the continuous data feed includes a ventilator rate, a respiratory rate, a positive inspiratory rate, a positive end expiratory rate, and a mean airway pressure. Discrete information associated with the ventilator is received. In embodiments, the discrete information includes endotracheal tube (ETT) size, ETT placement, ETT mode changes, ETT events, and ETT status. Additional information including blood gas results, sedation/paralytic medication information, and calculations, the calculations determined by ventilator data from the continuous data feed and/or electronic medical record (EMR) data received from the EMR is received. Data received from the ventilator is displayed. In embodiments, the data includes the continuous data feed, the discrete information, the additional data, ventilator pressure waveforms, patient-ventilator system check information, and diagnostic images.
A biometric sensor may include a scanner configured to capture a biometric data and an adjustment mechanism configured to respond to a force applied to the biometric sensor by shifting the biometric sensor from a neutral position to an adjusted position. The adjustment mechanism may be configured to respond to the removal of the force by returning the biometric sensor to the neutral position. While the biometric sensor is in the neutral position, the scanner may be capable of capturing a biometric data of a majority of users interacting with the apparatus. Accordingly, the biometric sensor may be able to operate with minimal adjustments. The biometric sensor may be part of a dispensing cabinet such that the biometric data captured by the biometric sensor may be used to control access to the dispensing cabinet. Related methods are also disclosed.
PURPOSE:To weaken a side effect while taking advantage of the endotoxin neutralizing effect of polymixin by immobilizing the polymixin on a fibrous carrier having the substituent selected from an alpha-acyl halide group, benzyl halide group and isocyanic acid group, thereby preparing the endotoxin neutralizer. CONSTITUTION:The endotoxin neutralizer is prepd. by immobilizing the polymixin to the fibrous carrier having the substituent selected from the alpha-acyl halide group, the benzyl halide group and the isocyanic acid group. The fibrous carrier is selected from polystyrene fibers or crosslinked polystyrene fibers, acrylic acid acrylonitride copolymer fibers and polyvinyl alcohol fibers having a carboxyl group. Since the endotoxin neutralizer is formed by immobilizing the polymixin at a high density, the neutralizer is capable of decomposing and nontoxicating the endotoxin in a soln. Since the polymixin does not elute into the soln., the soln. treated with the neutralizer does not exhibit toxicity.
PURPOSE:To provide a one-pack type hairdye capable of dyeing hair without causing the skin troubles, and giving moistness, smoothness and gloss to the hair, by using levulic acid and a dye such as triphenylmethane dye, azo dye, etc. and adjusting the pH of the mixture within a specific acidic range. CONSTITUTION:A one-pack type hairdye containing 5-25% levulic acid, added with a dye such as triphenylmethane dye, azo dye, quinoline dye, thiazole dye, xanthene dye, indigoide dye, anthraquinone dye, etc. and adjusted to 1.5-4.5pH. Dyeing of hair in desired color with excellent dyeing effect can be achieved easily by this hairdye, without causing adverse effect to the human body, e.g. the damages to the skin. The pH-adjusting agent is e.g. phosphoric acid, citric acid, etc.
A method of mercury-free photochemical micro-/nano-encapsulation of an active material is a process for obtaining micro-/nano-capsules by means of curing by UV LED radiation at ambient or even cold temperatures. A stirrer photo-reactor made from glass or transparent plastics can be used but mixed flow reactor could be also employed. Appropriate mixing is sufficient to expose all droplets, which contain an active material surrounded by curable-shell materials in the emulsion to the LED radiation. Using the optimum light intensities and reactions' times is critical for encapsulating the active material with a high efficiency and producing a high quality micro-/nano- capsules, Solar monochromator device can also be used as long as it generate the same radiation with a narrow/single wavelengths as the LED device. Light emitted diode (LED) is a mercury-free UV radiation source with a long operating life time and an instant ON-Off. it has a high efficiency, a very low cooling requirements and cost-efficient in photochemical encapsulation. It reduces the time of microencapsulation from 6 hours to a less than 5 minutes. It has a significant decrease in manufacturing cost, waste-water, unconverted monomers, and leftover active phase change material (PCM) compared to other methods. Conversion of more than 90% of monomers can be achieved, and encapsulation efficiency can reach 100% at optimum conditions. This is in addition to the ability of this invented technology for encapsulate volatile and heat sensitive active materials at ambient as well as low temperatures. Normal glass or transparent plastics can be used as a reactor material. Only the matched useful wavelength radiation is emitted by LED without having other wavelengths which might have a bad impact on the encapsulation process.
In Group A, adjuvant radio-chemotherapy is applied. The radiotherapy is performed according to Radiation Method A. The regimen of chemotherapy is cisplatin 30mg/m2 every week.
Metallic selenides or tellurides are prepared in the colloidal state, or in colloidal solution, by the action of selenium or tellurium compounds on metallic compounds in presence or absence of a protective colloid.  The latter, if used, may be gelatin, proteids, gum arabic, starch, dextrin, &c., or the water-soluble alkyl derivatives of polysaccharides.  These last are of value in that their aqueous solutions coagulate on warming, carrying down with them other colloid substances present, and redissolve on cooling.  This property allows the selenides or tellurides to be purified by washing.  In an example, 300-700 parts of 1 per cent auric chloride solution are mixed with 200 parts of a 3 to 10 per cent solution of a water-soluble alkyl derivative of a polysaccharide, such as methyl or ethyl cellulose, and the mixture treated with hydrogen selenide.  The olive-brown hydrosol of gold selenide is warmed to 50-80 DEG  C., when the alkyl cellulose coagulates, carrying the metallic compound with it.  The precipitate is filtered in a hot water funnel and washed.  It may then be dried, or dissolved in cold water.  Other methods of purification, such as dialysis, may be employed. Selenides or tellurides of silver, mercury, copper, tin, iridium, platinum, palladium, osmium, and other metals may be prepared in the same way, or other compounds of selenium or tellurium may replace the hydrogen compound.
PURPOSE:To obtain a humectant excellent in both effects and feeling of use. CONSTITUTION:A skin humectant for external use containing an extract of a saffron as an active ingredient. The extract of the saffron refers to an extract obtained by extracting ingredients of a stigma and a stylar upper part of the saffron. The aforementioned extract may be prepared by a method for drying e.g. the stigma and stylar upper part, adding a solvent (e.g. water, a 30-70wt.% aqueous solution of ethanol, ethanol, propylene glycol, 1,3-butylene glycol or isopropanol) to the dried stigma or stylar upper part, extracting the ingredients at ambient temperature for several days (e.g. 5-8 days) and filtering the obtained liquid.
This invention relates to novel 3-(1-substitutedpyrazoyl)-2-oxindole derivatives which are inhibitors of prostaglandin H2? synthase, 5-lipoxygenase and interleukin-1 biosynthesis. The compounds of the invention are useful as inhibitors of prostaglandin H2? synthase and interleukin-1 biosynthesis, per se, and as analgesic, antiinflammatory and antiarthritic agents in the treatment of chronic inflammatory diseases. This invention also relates to pharmaceutical compositions comprising said 3-(1-substitutedpyrazoyl)-2-oxindole derivatives; to methods of inhibiting prostaglandin H2? synthase and biosynthesis of interleukin-1; and to treating chronic inflammatory diseases in a mammal with said compounds. Further, this invention relates to certain novel compounds useful as intermediates in the preparation of the 3-(1-substitutedpyrazoyl)-2-oxindole derivatives of this invention and to a process for the preparation of the 3-(1-substitutedpyrazoyl)-2-oxindole derivatives.
Overweight and obesity are the most common metabolic disorders affecting the U.S. with 31% of adults and 16% of adolescents now meeting Centers for Disease Control criteria for these conditions. As the obesity epidemic has unfolded, so too has the increase in prevalence of abnormalities of carbohydrate metabolism. The single most effective treatment for type 2 diabetes in severely obese adults may be bariatric surgery, a procedure that is most commonly performed in the 5th and 6th decades of life. While it is clear that rapid and profound weight loss can significantly improve carbohydrate metabolism in adults, it is not clear to what degree type 2 diabetes is reversible in these patients. The pathophysiology of type 2 diabetes in adolescents and children is not well understood and no studies have yet examined the effect of surgical weight loss on insulin resistance, insulin secretion, or glucose tolerance in severely obese young people. However, it seems likely that bariatric surgery could improve these conditions in youth. Understanding the relative benefits of surgically induced weight reduction on carbohydrate metabolism in adolescents compared to older subjects is important for determining optimal timing of this intervention. This knowledge may also lead to key insights into obesity-induced diabetes. In this project we will test the hypothesis that bariatric surgical intervention will more effectively improve insulin resistance, β cell dysfunction, and glucose tolerance in adolescents compared to adults. Three specific aims are proposed: 1) To compare the derangements of carbohydrate metabolism among very severely obese (body mass index ≥ 40 kg/m2) adolescents and adults referred for bariatric surgery; 2) To assess improvement in carbohydrate metabolism longitudinally (during and after surgical weight loss) comparing differences in the mechanisms of improvement between the two age groups; 3) To compare major complications in the two age groups following bariatric surgery. These data will provide critical information about age-related metabolic outcomes of bariatric surgery and could inform the design of larger studies to examine the role of early bariatric surgery in management of disorders related to insulin resistance in patients at high risk for these conditions.
A method of extracting cannabinoids from hemp and/or of producing a whole hemp extract lacking .DELTA.9-THC is herein described. The industrial hemp is harvested and the chaff is thrashed from the seeds. The chaff is then ground and the ground chaff is extracted with an organic solvent. The extract is then loaded onto a chromatographic column selected to fractionate specific cannabinoids. In one embodiment, .DELTA.9-THC is fractionated out of the extract, producing a whole hemp extract lacking .DELTA.9-THC . In other embodiments, specific cannabinoids of interest are fractionated out, thereby producing purified cannabinoids.
Posttraumatic stress disorder (PTSD) and substance use disorder (SUD) often co-occur. PTSD+SUD comorbidity is associated with more severe PTSD, worse treatment outcomes for substance use, greater suicide risk and worse functioning than having one of these disorders. First-line treatments for PTSD, particularly Prolonged Exposure Therapy (PE), are effective in treating PTSD among those with a SUD, and delivering these treatments concurrent to SUD programming is recommended by the VA/DoD Clinical Practice Guidelines. While PE is one of the most effective treatment options for PTSD among those with PTSD+SUD, effects are smaller and dropout is higher than among people with PTSD without a SUD. A promising way to enhance outcomes is to offer PE in a massed format (M-PE; i.e., multiple sessions per week instead of once weekly). M-PE has been shown to be effective in improving PTSD symptoms and substantially reducing dropout in military and Veteran populations. Preliminary findings suggest M-PE delivered concurrent to intensive SUD programming is a promising strategy that warrants further study. Evaluating the effectiveness of M- PE delivery in of SUD intensive outpatient programming (IOP) in improving PTSD and other mental health outcomes and reducing dropout as compared to weekly PE delivery (W-PE) is the necessary next step in this critical research.

The primary goal of this project is to determine if a promising way to treat PTSD among those with SUD, M-PE, will help Veterans with their PTSD symptoms and lead to better treatment completion rates more than PE delivered weekly and if the massed format will reduce substance use comparably to weekly PE among those in intensive SUD treatment. The study will also evaluate if M-PE helps Veterans function better and feel less depressed. M-PE is a one-on-one talk therapy that is delivered over twelve sessions several times a week. The therapy is brief because of the massed format so that it can be delivered at times when lengthy interventions may not be realistic, such as military mental health clinics on bases where military personnel may be getting ready to redeploy. The research team's preliminary work with Veterans in intensive SUD treatment showed M-PE to lead to improvements in PTSD and depression symptoms with no dropout, making this larger evaluation of M-PE compared to PE delivered in the traditional longer (weekly) format a critical next step. The study will accomplish this by randomly assigning participants who are in intensive SUD treatment to receive either M-PE or W-PE. The study will have 200 Veterans who served post 9/11 go through this study and the entire study is expected to take four years to complete. The study will run the study across four VAs (San Diego, Tampa, Chicago, and Atlanta).
Accurate detection of heterogeneous circulating tumor cells (CTCs) is critical as they can make tumor cells more aggressive, drug-resistant, and metastasizing. Although the leukocyte membrane coating strategy is promising in meeting the challenge of detecting heterogeneous CTCs due to its inherent antiadhesive properties, it is still limited by the reduction or loss of expression of known markers. Bioorthogonal glycol-metabolic engineering is expected to break down this barrier by feeding the cells with sugar derivatives with a unique functional group to establish artificial targets on the surface of tumor cells. Herein, an engineered leukocyte biomimetic colorimetric sensor was accordingly fabricated for high-efficient detection of heterogeneous CTCs. Compared with conventional leukocyte membrane coating, the sensor could covalently bound to the heterogeneous CTCs models fed with Ac4ManNAz in vitro through the synergy of bioorthogonal chemistry and metabolic glycoengineering, ignoring the phenotypic changes of heterogeneous CTCs. Meanwhile, a sandwich structure composed of leukocyte biomimetic layer/CTCs/MoS2 nanosheet was formed for visual detection of HeLa cells as low as 10 cells mL-1. Overall, this approach can overcome the dependence of conventional cell membrane biomimetic technology on specific cell phenotypes and provide a new viewpoint to highly efficiently detect heterogeneous CTCs.
After polypectomy with a suitable method, either cold snare polypectomy, hot snare polypectomy, endoscopic mucosal resection, or endoscopic submucosal dissection, we will monitor if immediate polypectomy bleeding occurs. If immediate bleeding occurs, we will apply standard endoscopic therapy by either local injection of diluted epinephrine, heater probe coagulation, and/or hemoclipping. If there is no immediate bleeding, we will apply prophylactic clipping in high-risk patients with polyp size ≥ 1cm. After then, we will spray 3g of sucralfate powder through colonoscopy precisely on the polypectomy wound in the intervention group.
Participants in the guideline group will also need to complete a PCT test within 2 hours after randomization, however, the laboratory will save the results and do not sent back to the clinician. The clinician will make an antibiotic prescribing decision on the basis of the recommendations of GOLD guideline. The guideline recommend the following patients to receive antibiotic therapy. Patients with exacerbations of COPD who have three cardinal symptoms: increase in dyspnea, sputum volume, and sputum purulence; have two of the cardinal symptoms, if increased purulence of sputum is one of the two symptoms; or require mechanical ventilation (invasive or noninvasive).
PURPOSE: A polynucleotide delivering complex containing RVG peptide-conjugated cationic polymers is provided to effectively and safely deliver polynucleotides to target cells. CONSTITUTION: A polynucleotide delivering complex contains RVG(rabies virus glycoprotein) peptide-conjugated cationic polymers. The polymers have ester bond, amide bond, disulfice bond, phosphate bond, or combination thereof. The cationic polymers are polyethylene imine(PEI), poly-L-lysine(PLL), chitosan, or dendrimer. The polynucleotide delivering complex has non-peptidyl polymers between the RVG peptide and cationic polymers. The non-peptidyl polymers are polyethylene glycol.
The group will Participate in an physical exercise program twice a week. This program consists of 20 minutes of aerobic exercises of low intensity (2-4 on the Borg scale) in the rhythm of different songs that encourage their implementation. After these exercises will be performed five minutes of stretching exercises.
The invention discloses a flavonoid compound as well as a preparation method and application thereof. The flavonoid compound is separated from whole herb of leguminosae Desmodiumoxyphyllum, and is named as desmodium BA, the English name of the flavonoid compound is oxyphyllumflavoneA, the molecular formula is C21H16O6, and the flavonoid compound has the following structure as shown in the specification. The preparation method of the flavonoid compound comprises the following steps: by adopting the whole herb of Desmodiumoxyphyllum as a raw material, extracting extractum, extracting an organic solvent, performing MCI discoloration, performing silica gel column chromatography, and performing high-pressure liquid phase chromatographic separation. The application refers to the application of the flavonoid compound in preparing anti-cancer medicaments. By virtue of cytotoxic activity experiments, desmodium A shows relatively good cytotoxic activity to five strains of cells namely NB4, A549, SHSY5Y, PC3 and MCF7. The flavonoid compound disclosed by the invention is simple in structure and good in activity, can be used as a lead compound of the anti-cancer medicaments, and has relatively good application prospects.